Navigation

Glioblastoma - bevacizumab [ID80]

Bevacizumab for the treatment of recurrent glioblastoma

Status: Suspended
Expected date of issue: TBC
Referral date: November 2008
Process: STA
Notes:

The Department of Health asked the Institute to conduct an appraisal of bevacizumab for the treatment of recurrent glioblastoma and to provide guidance on its use to the NHS in England and Wales.

The Institute has noted that the Committee for Medicinal Products for Human Use (CHMP) recently adopted a negative opinion on extending the current indication of bevacizumab (Avastin) to include use in patients with recurrent glioblastoma. For further information please click on the following link: http://www.emea.europa.eu/pdfs/human/opinion/Avastin_Q&A_74620809en.pdf  

NICE has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update this webpage if the situation changes.

Topic area:
  • Cancer
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.